EHV-1 General Information

What is EHV-1?

EHV-1 (equine herpesvirus-1) is one of a large group of DNA viruses causing potentially serious disease in horses and other species. EHV-1 has two forms: one that causes abortion in mares and one that causes respiratory infection and neurological symptoms. The above cited outbreaks have involved the EHV-1 respiratory/neurological form of the virus causing a condition known as Equine Herpes Myeloencephalopathy (EHM).

EHV-1 is contagious and is spread by direct horse-to-horse contact, by contaminated hands, equipment and tack, and, for a short time, through aerosolization of the virus within the environment of the stall and stable.

What are the Clinical Signs of EHV-1?

The initial clinical signs of the infection may be nonspecific and include fever of 102°F or greater. Fever may be the only abnormality observed. Other presenting signs may be combinations of fever and respiratory symptoms of nasal discharge and cough. Some horses have reddish mucous membranes.

Horses with neurological disease caused by EHV-1 infection can soon become uncoordinated and weak and have trouble standing. Difficulty urinating and defecating may also occur. Often the rear limbs are more severely affected than the front. Signs of brain dysfunction may occur as well, including extreme lethargy and a coma-like state.

The incubation period of EHV-1 infection is HIGHLY VARIABLE, depending on the host, on the virulence of the virus, and on environmental and other factors such as stress. The AVERAGE incubation period is 4 to 7 days, with the majority of cases being 3 to 8 days, but with some taking up to 14 days. When neurological disease occurs, it is typically 8 to 12 days after the primary infection involving fever. In most cases, horses exposed to EHV-1 will develop a fever and possibly nasal discharge and then go on to recover.

EHV-1 Vaccination

Commercially available vaccines for EHV-1 include two single-component inactivated vaccines (Pneumabort K and Prodigy) marketed for the prevention of abortion in pregnant mares; several multicomponent inactivated vaccines (Prestige, Calvenza, Innovator); and one MLV vaccine (Rhinomune) for the prevention of respiratory disease induced by EHV-1 and EHV-4. Each of these vaccines induce some, but not all, of the desired components of the immune response in the horse. Therefore, it is not surprising that NONE induces sterile immunity or complete protection from clinical disease. The best that can be hoped for is a reduction in the severity of clinical signs and in the amount of EHV-1 shed by vaccinated horses that do become infected.

There is evidence that viral shedding is reduced in horses with high circulating titers of virus-neutralizing (VN) antibody, as well as in those that have been vaccinated recently with the Rhinomune MLV vaccine. Of the available inactivated vaccines, Calvenza and both high antigenic mass vaccines marketed for prevention of abortion (Pneumabort K and Prodigy) stimulate the highest levels of VN antibody in experimental horses. One recent study to test the efficacy of Rhinomune against challenge with a "neuropathogenic" strain, and a challenge study performed almost 30 years ago to test the efficacy of Pneumabort K in preventing abortion, provided some evidence that these vaccines may have a place in control of outbreaks of EHM. The low number of horses enrolled in these studies justifies caution in interpretation of the results; however, a lower proportion of recently vaccinated horses developed EHM after challenge as compared to control unvaccinated horses in both studies.

On premises with confirmed clinical EHV-1 infection (any form), booster vaccination of horses that are likely to have been exposed already is not recommended. However, it seems rational to booster vaccinate nonexposed horses as well as horses that must enter the premises with one of the four vaccines listed above if they have not been vaccinated against EHV-1 within the past 60 days. This approach relies on the assumption that the immune system of most mature horses has already been "primed" by prior exposure to EHV-1 antigens through field infection or vaccination and can therefore be "boosted" within 7 to 10 days of administration of a single dose of vaccine.

While this approach does not guarantee protection of individual horses against the potentially fatal neurological form of EHV-1, the hope is that reduced nasal shedding of infectious EHV-1 by recently vaccinated horses will indirectly help protect other horses by reducing the dose of virus to which they are exposed.

CLICK HERE to read the full article provided by UC Davis Veterinary Medicine.

Click here to view Rhinopneumonitis vaccines.

Nutritional/Immune Support Products:

Tri-Mune

L-Lysine